Meglu ER Tablet 750 mg contains Metformin Hydrochloride, a long-acting (extended-release) oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Metformin belongs to the biguanide class, acting primarily to reduce hepatic glucose production and improve insulin sensitivity in peripheral tissues.

The extended-release (ER) formulation of Meglu allows gradual release of metformin over 12–24 hours, maintaining steady blood glucose levels throughout the day. This minimizes fluctuations in blood sugar and reduces gastrointestinal side effects commonly associated with immediate-release metformin. Meglu ER Tablet 750 mg is ideal for patients seeking once-daily or simplified dosing for improved adherence and convenience.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Meglu ER Tablet 750 mg is indicated for:

• Type 2 diabetes mellitus in adults and adolescents (≥10 years)

• Monotherapy in patients not adequately controlled with diet and exercise alone

• Combination therapy with other oral antidiabetic agents or insulin when monotherapy is insufficient

• Management of metabolic disorders associated with insulin resistance

• Prevention of type 2 diabetes in high-risk individuals, under medical supervision

Meglu ER helps maintain fasting and postprandial blood glucose levels, reducing the risk of long-term diabetes-related complications, while supporting weight management and overall metabolic health.

Dosage and Administration

Recommended dosage:

• Adults: Typically 750 mg once daily with the main meal, or as prescribed by a healthcare professional

• Maximum daily dose: 2,000 mg–2,500 mg, divided into 1–2 ER tablets depending on clinical response

• Pediatric patients: Dose determined by weight and physician guidance

Administration guidelines:

• Swallow tablets whole; do not crush, chew, or break, as this can alter the extended-release mechanism

• Take with the main meal to improve absorption and reduce gastrointestinal discomfort

• Maintain a consistent daily schedule for optimal glycemic control

• Regular monitoring of blood glucose levels is recommended to assess treatment efficacy

Precautions and Warnings

• Lactic acidosis: A rare but serious complication; risk increases in patients with renal impairment, hepatic disease, severe infection, dehydration, or excessive alcohol intake

• Renal function monitoring: ER metformin should be used with caution in patients with moderate renal impairment and is contraindicated in severe renal disease

• Hepatic impairment: Use carefully in patients with liver disease

• Contrast studies: Temporarily discontinue before iodinated contrast imaging to reduce risk of renal complications

• Pregnancy and breastfeeding: Considered safe under medical supervision; consult a healthcare professional

• Drug interactions: Certain medications, including diuretics and corticosteroids, may affect glucose control

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Meglu ER Tablet 750 mg is generally well tolerated. Common side effects include:

• Mild gastrointestinal issues: nausea, diarrhea, abdominal discomfort, or bloating

• Metallic taste in the mouth

• Rarely, long-term use may result in vitamin B12 deficiency

Most side effects are mild and transient, often resolving with continued use. Severe reactions, including lactic acidosis, are extremely rare but require immediate medical attention.

Storage

Store in a cool, dry place below 25°C, away from light and moisture. Keep the tablets in their original packaging and out of reach of children.

Meglu ER Tablet 750 mg (Metformin Hydrochloride) offers effective, long-acting blood glucose control, minimizing side effects and improving adherence for patients with type 2 diabetes. Its extended-release formulation provides convenient once-daily dosing, supporting long-term metabolic health and glycemic stability.